<DOC>
	<DOCNO>NCT00001407</DOCNO>
	<brief_summary>This study determine dose recombinant interferon-gamma safe effective treat multiple drug-resistant tuberculosis . Recombinant interferon-gamma genetically engineer form substance normally produce body use boost immune function . Patients 5 year age old multiply drug-resistant tuberculosis may eligible study . Participants admit either NIH Clinical Center Bethesda , Maryland , Texas Center Infectious Diseases San Antonio South Texas Hospital Valley Baptist Hospital , Harlingen , Texas . On admission , patient medical history , physical examination , blood urine test , sputum culture , X-rays , pulmonary function test compute tomography ( CT ) scan . CT produce 3-dimensional image body tissue organs small section . For procedure , patient lie still table surrounded scanner . All patient continue treatment anti-tuberculosis antibiotic study period may elect whether take gamma interferon addition antibiotic . Five patient receive antibiotic treatment , 5 receive one 3 dos ( 0.025 , 0.05 0.1 milligram per square meter body surface area ) interferon-gamma injected skin 3 time week . The patient caregiver teach give injection , similar insulin injection diabetes . Patients isolation hospital start therapy sputum sample show evidence tuberculosis 3 consecutive week . Following , repeat test do admission ( except CT ) follow-up visit ( 1- 2-day hospitalization ) 3 , 6 , 9 , 12 , 15 , 18 24 month start therapy . Patients take interferon gamma blood drawn frequently ( monthly ) first 6 month , patient lung infection sputum sample collect frequently-weekly first 3 month three consecutive negative sample obtain monthly throughout course therapy . Patients lung infection also repeat CT scan 6 12 month interferon gamma . In one two patient drug , blood drawn frequently follow one injection gamma interferon ( injection 0.25 , 0.5 , 1 , 6 , 12 , 18 , 24 48 hour ) see difference blood level drug detect .</brief_summary>
	<brief_title>Interferon Gamma Drug Resistant Tuberculosis</brief_title>
	<detailed_description>This phase I/II , control , open label , dose escalation study determine tolerance , toxicity , clinical effect administration interferon-gamma clinical condition immune function patient multiply drug resistant M. tuberculosis infection ( MDRTB ) . The study drug ( interferon gamma ) administer subcutaneously three time week three dose level ( 0.025 mg/m ( 2 ) , 0.05 mg/m ( 2 ) , 0.1 mg/m ( 2 ) ) one year addition anti-tuberculous medication , determine vitro sensitivity .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>ELIGIBLITY CRITERIA : Clinical microbiologic/histologic demonstration MDRTB , either disseminate ( i.e . infection 2 noncontiguous site ) pulmonary . Preserved renal function ( creatinine less equal 2 mg/100 ml ; le equal 2+ proteinuria ) . Preserved hepatic function ( bilirubin less equal 1.5 mg/100 ml ; prothrombin time le equal 1.3x control ) . Preserved hematologic function ( WBC great equal 3000/mm3 ; granulocyte great 1500/mm3 ; platelet great equal 100,000/mm3 ) . Patients childbearing potential may enter use effective contraception negative serum urine HCG within one week begin therapy . EXCLUSION CRITERIA : Presence cause secondary immunodeficiency HIV malignancy . Currently receive cytotoxic therapy , receive within last 3 month . Pregnant lactate woman may enter . Patients known seizure disorder may enter . Patients know symptomatic cardiac disease , arrhythmias coronary artery disease may enter . Patients unable , judgment PI , comply treatment regimen exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>Cytokines</keyword>
	<keyword>Mycobacteria</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Multiple Drug Resistant Tuberculosis</keyword>
</DOC>